title: Changes induced by estradiol-ethylenediamine derivative on perfusion pressure and coronary resistance in isolated rat heart: L-type calcium channel.
abstract: OBJECTIVE
  The present study was designed to investigate the effects of estradiol-ethylenediamine derivative on perfusion pressure and coronary resistance in rats. An additional aim was to identify the molecular mechanisms involved.
  
  
  METHODS
  The Langendorff model was used to measure perfusion pressure and coronary resistance changes in isolated rat heart after estradiol-ethylenediamine derivative alone and following compounds; tamoxifen (estrogen receptor antagonist), prazosin (alpha1 adrenoreceptor antagonist), metoprolol (selective beta1 receptor blocker), indomethacin (prostanglandin synthesis inhibitor) and nifedipine (L-type calcium-channel inhibitor).
  
  
  RESULTS
  The results show that estradiol-ethylenediamine derivative [10(-9) mmol] significantly increased perfusion pressure (p = 0.005) and coronary resistance (p = 0.006) in isolated rat heart. Additionally, the effect of estradiolethylenediamine on perfusion pressure [10(-9) to 10(-4) mmol] was only blocked in the presence of the L-type calcium-channel (nifedipine).
  
  
  CONCLUSIONS
  These data suggest that the effect of estradiol-ethylenediamine on perfusion pressure and vascular coronary involves activation of the L-type calcium channel through a non-genomic molecular mechanism.
authors.affiliation: Laboratorio de Investigacion en Ciencias Biologicas y Farmacoqiimica de la Facultad de Ciencias Quimico-Biologicas, Universidad Autonoma de Campeche, Col Buenavista C.P. Campeche Cam., Mexico. lauro_1999@yahoo.com
authors.forename: Lauro Figueroa
authors.initials: LF
authors.lastname: Valverde
authors.forename: Francisco Diaz
authors.initials: FD
authors.lastname: Cedillo
authors.forename: Maria Lopez
authors.initials: ML
authors.lastname: Ramos
authors.forename: Elodia Garcia
authors.initials: EG
authors.lastname: Cervera
authors.forename: Karen
authors.initials: K
authors.lastname: Quijano
authors.forename: Johani
authors.initials: J
authors.lastname: Cordoba
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology; D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism*; D003326:Coronary Circulation / Q000187:drug effects*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology; D005029:Ethylenediamines / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008790:Metoprolol / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013629:Tamoxifen / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D016861:Cyclooxygenase Inhibitors; D004965:Estrogen Antagonists; D005029:Ethylenediamines; D013629:Tamoxifen; D004958:Estradiol; D008790:Metoprolol; D009543:Nifedipine; D011224:Prazosin; D007213:Indomethacin